HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

419.757

-17.440-3.99%

Number of Gainers:5

Number of Losers:27

Number of Flat:2

PE:- -

High:441.043

Open:436.588

Low:416.263

Close:437.197

Loading ...

BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal

BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation

BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG

Akeso Announces Completion of Patient Enrollment in the Phase Iii Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

THOMSON REUTERS

CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl

THOMSON REUTERS

Hbm Holdings - Upfront Payment Received Under License Agreement With Windward Bio Ag for Hbm9378/Skb378

THOMSON REUTERS

Ascentage Pharma Group International - Olverembatinib Given Breakthrough Therapy Designation by Center for Drug Evaluation of China Nmpa

THOMSON REUTERS

Subdued Growth No Barrier To Suzhou Basecare Medical Corporation Limited's (HKG:2170) Price

Simply Wall St.

Immunotech Biopharm Ltd (HKG:6978) Top Key Executive Zheng Tan, the company's largest shareholder sees 15%reduction in holdings value

Simply Wall St.

BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Olverembatinib Granted Breakthrough Therapy Designation for Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All)

THOMSON REUTERS

Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%

MT Newswires Live

BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio

Alphamab Oncology to Turn to 2024 Profit

MT Newswires Live

Retail investors are Ascentage Pharma Group International's (HKG:6855) biggest owners and were hit after market cap dropped HK$720m

Simply Wall St.

Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":419.75656,"timestamp":1741594084391,"preClose":437.19687,"halted":0,"volume":125062844,"delay":0,"changeRate":-0.039891,"change":-17.440308,"pbRate":3.43319,"amount":2228559126,"amplitude":0.056681,"prevYearClose":331.1933,"fiveDayClose":410.09,"twentyDayClose":340.813,"turnoverRate":0.004845,"marketCap":234571806688,"floatMarketCap":221135631584,"peRate":-17.305245},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":441.04327,"amplitude":0.056681,"preClose":437.19687,"low":416.2626,"pbRate":"3.43319","latestPrice":419.75656,"volume":125062844,"delay":0,"open":436.5877,"prevYearClose":331.1933,"prevWeekClose":437.197,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":410.09,"twentyDayClose":340.813,"sixtyDayClose":341.701,"secType":"PLATE","market":"HK","turnoverRate":0.004845,"peRate":-17.305245,"marketCap":234571806688,"floatMarketCap":221135631584,"timestamp":1741594084391,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":5,"down":27,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517901950","title":"BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2517901950","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517901950?lang=en_us&edition=fundamental","pubTime":"2025-03-06 12:08","pubTimestamp":1741234095,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Hbm at 3-year peak on getting paid for license deal** Shares of Chinese immunology diseases therapeutics developer Hbm Holdings Ltd 2142.HK rise 4.8% to HK$6.27, their highest since January 2022, and on course for second session of gains** Hbm says co, as a licensor in a license agreement for product HBM9378/SKB378, has received an upfront payment from licensee Windward Bio AG, which will bolster co's cash reserves** It gives no further details** Hong Kong's healthcare index .HSCIH climbs 1.1%, Hang Seng Index .HSI rises 2.5%** Stock up 221.5% YTD    ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL2N3PP04E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02142","BK1583"],"gpt_icon":0},{"id":"2517716729","title":"BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517716729","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517716729?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:52","pubTimestamp":1741222374,"startTime":"0","endTime":"0","summary":"BRIEF-Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation March 6 (Reuters) - Ascentage Pharma Group International 6855.HK:OLVEREMBATINIB GIVEN BREAKTHROUGH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2517971674","title":"BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971674","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517971674?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:52","pubTimestamp":1741222350,"startTime":"0","endTime":"0","summary":"BRIEF-HBM Holdings Says Upfront Payment Received Under License Agreement With Windward Bio AG March 6 (Reuters) - Hbm Holdings Ltd 2142.HK:UPFRONT PAYMENT RECEIVED UNDER LICENSE AGREEMENT WITH WINDWARD BIO AG FOR HBM9378/SKB378Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2517979311","title":"Akeso Announces Completion of Patient Enrollment in the Phase Iii Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517979311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517979311?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:30","pubTimestamp":1741221002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA48VPCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1720050803.USD","09926","LU2488822045.USD","BK1574","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1794554557.SGD","BK1161","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348783233.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2517976361","title":"CStone Submits Clinical Trial Application in Australia for Cs5001 (Ror1 ADC) in Combination With First-Line Standard-of-Care for Dlbcl","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517976361?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:10","pubTimestamp":1741219803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nTUA2T0MDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2517975240","title":"Hbm Holdings - Upfront Payment Received Under License Agreement With Windward Bio Ag for Hbm9378/Skb378","url":"https://stock-news.laohu8.com/highlight/detail?id=2517975240","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517975240?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:00","pubTimestamp":1741219250,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2517975834","title":"Ascentage Pharma Group International - Olverembatinib Given Breakthrough Therapy Designation by Center for Drug Evaluation of China Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2517975834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517975834?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:43","pubTimestamp":1741218211,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO0WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2517307132","title":"Subdued Growth No Barrier To Suzhou Basecare Medical Corporation Limited's (HKG:2170) Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2517307132","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517307132?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:25","pubTimestamp":1741217117,"startTime":"0","endTime":"0","summary":"It's not a stretch to say that Suzhou Basecare Medical Corporation Limited's ( HKG:2170 ) price-to-sales (or \"P/S...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-2170/suzhou-basecare-medical-shares/news/subdued-growth-no-barrier-to-suzhou-basecare-medical-corpora","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","02170","BK1222","BK1597"],"gpt_icon":0},{"id":"2517213101","title":"Immunotech Biopharm Ltd (HKG:6978) Top Key Executive Zheng Tan, the company's largest shareholder sees 15%reduction in holdings value","url":"https://stock-news.laohu8.com/highlight/detail?id=2517213101","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517213101?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:09","pubTimestamp":1741216185,"startTime":"0","endTime":"0","summary":"Key Insights Insiders appear to have a vested interest in Immunotech Biopharm's growth, as seen by their sizeable...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6978/immunotech-biopharm-shares/news/immunotech-biopharm-ltd-hkg6978-top-key-executive-zheng-tan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2517978453","title":"BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978453","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978453?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:03","pubTimestamp":1741215813,"startTime":"0","endTime":"0","summary":"BRIEF-Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)March 5 (Reuters) - Ascentage Pharma Group I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2517978965","title":"Olverembatinib Granted Breakthrough Therapy Designation for Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (All)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517978965","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517978965?lang=en_us&edition=fundamental","pubTime":"2025-03-06 07:01","pubTimestamp":1741215701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO16J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2517697559","title":"Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517697559","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517697559?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:39","pubTimestamp":1741160361,"startTime":"0","endTime":"0","summary":"Antengene  obtained new drug application approval for three indications of XPOVIO  from the Indonesia National Agency of Drug and Food Control, a Wednesday Hong Kong bourse filing said.The indications include a combination with bortezomib and dexamethasone used for the treatment of multiple myeloma in adult patients, a combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma, and as a monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients.Multiple myeloma is a cancer related to the white blood cells called plasma cells, while diffuse large B-cell lymphoma is cancer related to the white blood cells called lymphocytes.Shares of the company were up nearly 11% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1191","BK1583","06996"],"gpt_icon":0},{"id":"2517969313","title":"BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517969313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517969313?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:28","pubTimestamp":1741159699,"startTime":"0","endTime":"0","summary":"BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For XpovioMarch 5  - Antengene Corp Ltd 6996.HK:APPROVAL OF NDA BY INDONESIA NATIONAL AGENCY OF DRUG AND FOOD CONTROL FOR XPOVIOFurther company coverage: 6996.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06996","BK1583","BK1191"],"gpt_icon":0},{"id":"2517963731","title":"Alphamab Oncology to Turn to 2024 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2517963731","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517963731?lang=en_us&edition=fundamental","pubTime":"2025-03-05 14:52","pubTimestamp":1741157539,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  expects a profit of at least 150 million yuan for the year 2024, compared with a loss of around 210.6 million yuan a year prior, a Tuesday filing with the Hong Kong bourse said.The drugmaker attributed the anticipated turnaround to profit mainly to three license collaborations and sales revenue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2517911944","title":"Retail investors are Ascentage Pharma Group International's (HKG:6855) biggest owners and were hit after market cap dropped HK$720m","url":"https://stock-news.laohu8.com/highlight/detail?id=2517911944","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517911944?lang=en_us&edition=fundamental","pubTime":"2025-03-05 14:15","pubTimestamp":1741155303,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by retail investors in Ascentage Pharma Group International indicates that they...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/retail-investors-are-ascentage-pharma-group-internationals-h-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2517195939","title":"Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517195939?lang=en_us&edition=fundamental","pubTime":"2025-03-05 12:00","pubTimestamp":1741147235,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06996","BK1583","BK1574","BK1191"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":62}]}}